New Global Consortium to Advance First-Ever Clinical Testing of the Human Hookworm Vaccine in Sub-Saharan Africa

AMSTERDAM & WASHINGTON, DC – September 26, 2013 – The HOOKVAC consortium, led by the Academic Medical Center (AMC) at the University of Amsterdam, today announced it has been awarded a grant of six million Euros from the European Commission FP7 programme to expand the Sabin Vaccine Institute Product Development Partnership’s (Sabin PDP) work to develop and test a vaccine for human hookworm, a disease that infects 600-700 million of the world’s poorest people. Under this grant, the HOOKVAC consortium, which includes partners from the European Union, United States and Africa, will begin the first clinical testing of the human hookworm vaccine in the West African nation of Gabon.

Human hookworm, schistosomiasis, Chagas disease and leishmaniasis are some of the most devastating diseases in poverty with no licensed vaccine available.

Neglected Tropical Diseases (NTDs) are an important health issue in countries around the world. Most people don’t think about them at all, let alone know that some NTDs are also prevalent in the United States. The emerging threat of NTDs at home has been gaining attention recently, such as in this recent article, which appeared online in Discover.

PDPs Applaud Japan’s First Public-Private Partnership to Spearhead Innovation in Global Health

A new public-private partnership of the Japanese Government, the Bill &Melinda Gates Foundation and a group of private pharmaceutical companies seeks to foster and harness Japanese innovation to address diseases that disproportionately affect low- and middle-income countries.

Pages

Subscribe to RSS - PDP